KOSDAQBiotech & Pharma078140

Daebonglsco

₩6,680▼ 0.45%2026-11-18 close
Market Cap
₩74.1B
Turnover
₩200M
Volume
30K
Shares out.
11.1M
PER
23.0×
PBR
0.5×
EPS
₩294
Dividend Yield
0.74%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩50 per share · Prices as of the 2026-11-18 close

01

Report overview

Cosmetic materials lead; profit recovery still in progress

Cosmetic material sales have driven two straight years of revenue growth and a sharp operating profit rebound in the third quarter of 2026, but the 2025 operating profit decline and rising debt ratio remain items to track in the next periodic report.

  1. 1

    Sales reached KRW 102.1 billion in 2025, the first time above KRW 100 billion, and have risen for two consecutive years after the 2023 low.

  2. 2

    Operating profit fell from KRW 9.05 billion in 2024 to KRW 7.33 billion in 2025, while third-quarter 2026 operating profit rose to KRW 2.74 billion, up 257.0% year on year.

  3. 3

    Cosmetic materials are the main growth engine: first-half 2026 sales in this segment were about KRW 39.6 billion, roughly 63% of consolidated revenue, helped by demand for silicone substitutes tied to EU rules.

  4. 4

    Financial pressure has also grown: the debt-to-equity ratio rose from 25.4% in 2022 to 51.5% in 2025, and financing-related costs increased in the first half of 2026.

  5. 5

    The pharmaceutical raw materials unit has held sales roughly flat, and licensing of improved new drugs and supply of GLP-1 related ingredients remain expansion items.

02

Business structure

Daebonglsco is a specialty company in cosmetic materials and pharmaceutical raw materials, with two core segments. According to a Korean media tally of company data, first-half 2026 cosmetic materials sales were about KRW 39.6 billion, up 28.8% year on year and roughly 63% of consolidated revenue.

The company supplies more than 1,200 cosmetic and pharmaceutical materials to over 800 customers, with major Korean ODM manufacturers among its key clients.

Its material lineup is shifting toward high-value functional ingredients, including silicone-replacement emollients, wrinkle-improving peptides, and soothing or regenerative skin ingredients.

The pharmaceutical raw materials unit centers on olmesartan medoxomil, a hypertension drug ingredient, and SCMC, a respiratory-category ingredient, and its cumulative sales for the first three quarters of 2026 were roughly flat year on year.

Its clinical-testing subsidiary runs cosmetic human-application testing, and in the first nine months of 2026 that testing unit generated KRW 15.9 billion of the subsidiary's KRW 19.6 billion in cumulative sales, about 81%.

The company says it combines in-house material development with the subsidiary's testing capability to cover ingredient selection through efficacy verification. Under this structure, material sales and testing services form two revenue streams.

The company itself notes that material demand is sensitive to production plans and brand strategy changes at domestic customers.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩24.8B₩800M3.1%
2025Q4₩24.8B₩600M2.4%
2026Q1₩29.1B₩2B6.9%
2026Q2₩33.7B₩3.7B10.9%
2026Q3₩31.1B₩2.7B8.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩93.5B₩8.2B₩8.6B8.7%7.4%25.4%
2023₩87.6B₩3.8B₩4.2B4.3%3.5%27.2%
2024₩94B₩9.1B₩7.3B9.6%5.6%45.6%
2025₩102.1B₩7.3B₩10.1B7.2%7.1%51.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual sales moved from KRW 93.5 billion in 2022 to KRW 87.6 billion in 2023, a 6.3% decline, then rose to KRW 94 billion in 2024 (up 7.2%) and KRW 102.1 billion in 2025 (up 8.6%), with growth in both 2024 and 2025 following the 2023 low.

Operating profit went from KRW 8.17 billion in 2022 to KRW 3.8 billion in 2023 (down 53.5%), KRW 9.05 billion in 2024 (up 138.2%) and KRW 7.33 billion in 2025 (down 19.0%), making 2024 the largest year in the 2022 to 2025 range.

The operating margin over the same years was 8.7%, 4.3%, 9.6% and 7.2%, recovering in 2024 before falling again in 2025.

Net income attributable to controlling shareholders was KRW 8.63 billion in 2022, KRW 4.18 billion in 2023 (down 51.5%), KRW 7.34 billion in 2024 (up 75.5%) and KRW 10.1 billion in 2025 (up 37.0%), with 2025 the largest year.

Total net income including non-controlling interests was KRW 11.9 billion in 2025, a different figure from the controlling-shareholder number.

In 2025 operating profit fell while both profit measures rose, which suggests non-operating items may have weighed in, although the periodic report figures alone do not isolate the cause.

The debt-to-equity ratio climbed from 25.4% in 2022 to 51.5% in 2025, and at the end of 2025 total equity was KRW 174.9 billion, of which KRW 141.2 billion belonged to controlling shareholders, against total liabilities of KRW 90 billion.

Operating cash flow was KRW 8.78 billion in 2022, KRW 5.89 billion in 2023, KRW 14.3 billion in 2024 and KRW 8.91 billion in 2025.

On a quarterly basis, the fourth quarter of 2025 showed KRW 24.8 billion in sales, KRW 598 million in operating profit and a controlling-shareholder net loss of KRW 784 million, a swing into loss.

The first quarter of 2026 brought sales of KRW 29.1 billion (up 16.9% quarter on quarter) and operating profit of KRW 1.99 billion, while the controlling-shareholder net loss narrowed to KRW 12.65 million.

The second quarter returned to profit with sales of KRW 33.7 billion, operating profit of KRW 3.67 billion and controlling-shareholder net income of KRW 1.19 billion.

The third quarter recorded sales of KRW 31.1 billion, down 7.6% quarter on quarter but up 25.2% year on year, operating profit of KRW 2.74 billion and controlling-shareholder net income of KRW 2.82 billion. Net income attributable to controlling shareholders over the last four quarters totals KRW 3.21 billion.

A first-half 2026 semi-annual report coverage notes that selling and administrative expenses rose from KRW 9.4 billion to KRW 11.3 billion and financing costs rose from KRW 1.6 billion to KRW 6.3 billion.

05

Industry analysis

The cosmetic materials market is expanding as Korean beauty products go overseas and ODM production grows.

A Daishin Securities report noted that the company's cosmetic materials sales rose from KRW 11.2 billion in the second quarter of 2023 to KRW 21.6 billion in the second quarter of 2026, roughly doubling in three years. Exports reportedly grew 52% year on year in the first half of 2026.

On regulation, the EU restricts cyclic silicones D4, D5 and D6 in rinse-off cosmetics, creating demand for silicone-replacement materials. Reports date the restriction to June 2027, though one outlet described it as already in effect from June 2026, so the start date is not consistent across coverage.

Domestically, production plan adjustments and brand strategy changes at customers have raised uncertainty, and the company says it shifted from simple ingredient supply to integrated solution proposals.

Repeat orders from dermatologic cosmetics channels such as hospitals, pharmacies and Olive Young reflect the demand pattern. The pharmaceutical raw materials business mainly supplies domestic drugmakers, and its cumulative sales through the first three quarters of 2026 were roughly flat year on year.

Unlike many listed peers in the bio and pharma sector that center on new drugs or biologics, this company earns more from material sales and testing services, so the peer comparison basis differs.

Daishin Securities noted that supply of GLP-1 class drug ingredients alongside improved-drug licensing could increase the pharmaceutical unit's profit contribution.

06

Outlook

According to company statements, the subsidiary's backlog at the end of the third quarter of 2026 was KRW 8.6 billion, up 59% year on year, indicating a larger volume of orders that could convert into future sales.

Clinical-testing revenue is recognized as tests progress and finish after contracts are signed, so the speed of conversion matters more than the order size alone.

On the material pipeline, HRP-NMN, co-researched with Kolmar Korea, has been filed for a patent, and a natural thickener named Lipid Gum is in development with COSMAX.

The company also said it is developing a high-purity amino acid for cell culture with CJ CheilJedang and a microneedle-based hair-loss solution with KAIST. Coverage highlighted the timing of revenue contribution from new materials as a key question, and that timing is not yet visible in the reported quarterly figures.

In pharmaceuticals, the company is pursuing licensing of improved-new-drug raw materials and overseas commercialization of generic raw materials, and it plans to expand medical devices and improved drugs as part of a medical beauty portfolio.

For outside views, an article in early November 2026 reported that the Korea IR Council forecast 2026 consolidated sales of about KRW 126.8 billion and operating profit of about KRW 13.2 billion.

In a report in early November 2026, Daishin Securities pointed to possible profit improvement in both materials and pharmaceuticals in 2027. Annual results for 2026 are likely to be released around late February 2027, following the 2025 pattern, and that release will allow comparison with these outside forecasts.

07

Valuation

PER
23.0×
PBR
0.5×
ROE
2.2%
EPS
₩294
BPS
₩13,209
Dividend per share
₩50

The price-to-book ratio is below 1x, so the share price sits below book value per share attributable to shareholders. At the end of 2025 total equity was KRW 174.9 billion, of which KRW 141.2 billion belonged to controlling shareholders, and total liabilities were KRW 90 billion.

The dividend yield is in a low range, so interpretation of valuation centers more on changes in earnings scale than on dividends. The price-to-earnings ratio is sensitive to quarterly earnings swings, because net income attributable to controlling shareholders over the last four quarters totals only KRW 3.21 billion.

Third-quarter 2026 operating profit of KRW 2.74 billion improved the earnings level from the fourth quarter of 2025, but the earlier net loss means continuity still needs to be confirmed.

The debt-to-equity ratio rising from 25.4% in 2022 to 51.5% in 2025 is a capital structure factor to weigh when reading the premium or discount to net assets.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Structural growth in cosmetic material demand

One analysis showed cosmetic materials sales roughly doubling from KRW 11.2 billion in the second quarter of 2023 to KRW 21.6 billion in the second quarter of 2026. The drivers cited are Korean beauty exports and higher output at ODM clients.

Orders for silicone-replacement emollients tied to EU restrictions have also increased. Reported first-half 2026 exports rose 52% year on year.

Profit recovery and a return to quarterly profit

Third-quarter 2026 operating profit was KRW 2.74 billion, up 257.0% year on year, and controlling-shareholder net income was KRW 2.82 billion, up 138.1% quarter on quarter.

The company returned to profit in the second quarter of 2026 after a controlling-shareholder net loss of KRW 784 million in the fourth quarter of 2025. Cumulative operating margin was about 9%, a slight improvement from the prior year. The company attributes part of the net income recovery to non-operating items stabilizing.

Order backlog and joint development pipeline

The subsidiary's backlog at the end of the third quarter of 2026 was KRW 8.6 billion, up 59% year on year. HRP-NMN, co-researched with Kolmar Korea, has been filed for a patent, and a natural thickener is in development with COSMAX.

In pharmaceuticals, the company is pursuing licensing of improved-drug raw materials and overseas commercialization of generics.

09

Bear factors

Lower operating margin and rising costs

Operating profit in 2025 was KRW 7.33 billion, down 19.0%, and the margin fell to 7.2% from 9.6% in 2024. In the first half of 2026, sales grew but selling and administrative expenses rose from KRW 9.4 billion to KRW 11.3 billion, and the operating margin fell from 11.4% to 9.0%.

Third-quarter 2026 sales declined 7.6% from the prior quarter. Revenue growth has not fully translated into profit growth.

Financing costs and borrowing burden

Financing costs in the first half of 2026 reportedly rose from KRW 1.6 billion to KRW 6.3 billion, with currency forward losses of KRW 3.8 billion the largest component. Short-term borrowings reportedly rose from KRW 4.3 billion at the end of the prior year to KRW 12.7 billion.

The debt-to-equity ratio climbed from 25.4% in 2022 to 51.5% in 2025. If operating profit stalls, this burden could weigh more heavily on net income.

Stalled pharmaceutical unit and customer concentration

The pharmaceutical raw materials unit's cumulative sales through the third quarter of 2026 stayed roughly flat year on year. The company itself said cosmetic material demand is affected by production plan changes and brand strategy shifts at domestic customers.

If key ODM clients change production plans, material orders could fluctuate. The fourth quarter of 2025 also swung to a controlling-shareholder net loss of KRW 784 million.

10

Risk factors

Regulatory timing and customer concentration

The EU restriction on cyclic silicones is reported to take effect in June 2027, but one outlet described it as already in force from June 2026, so the timing is inconsistent across coverage. Orders for replacement materials could shift before and after enforcement.

Production plan adjustments at domestic customers were already cited as a source of uncertainty in 2025. Demand changes at a major ODM client could affect total material sales.

Financial and currency exposure

A report indicated that currency forward losses accounted for more than 60% of financing costs in the first half of 2026. As exports grow, exchange rate swings may have a larger effect on profit and loss. If rates or currencies move against the company while debt is rising, financing costs could climb again. Operating cash flow was KRW 8.91 billion in 2025, down from KRW 14.3 billion in 2024.

Execution and timing of business transition

Licensing of improved-drug raw materials, overseas commercialization of generics, and expansion into medical devices have been described as plans. The timing and scale of revenue from jointly developed materials are not yet visible in quarterly results.

Backlog at the subsidiary converts to revenue as tests progress, so recognition could be delayed. The longer the gap between plans and reported results, the less certain the durability of the profit recovery.

11

What to watch next

  1. Around late February 2027

    Expected release of fourth-quarter and full-year 2026 preliminary results. Full-year 2025 results were announced on February 27, 2026. Key items are whether a fourth-quarter net loss recurs and the full-year operating margin.

  2. By March 31, 2027

    Filing of the 2026 annual business report. It is the point to confirm audited full-year results, non-operating items, financing costs and debt structure on a disclosed basis.

  3. By May 15, 2027

    Filing of the first-quarter 2027 quarterly report. It will show how much of the KRW 8.6 billion subsidiary backlog converts to revenue and whether the operating margin holds near the second-quarter 2026 level.

  4. June 2027

    Scheduled enforcement of the EU restriction on cyclic silicones D4, D5 and D6. The check is whether demand for replacement emollients continues after enforcement.

12

Overall view

Daebonglsco's sales surpassed KRW 100 billion for the first time in its history in 2025, reaching KRW 102.1 billion, driven by stronger demand for cosmetic materials, and the company said cumulative sales through the third quarter of 2026 reached a record level of KRW 93.8 billion.

On profit, operating income recovered from the 2023 low to KRW 9.05 billion in 2024 before falling to KRW 7.33 billion in 2025, then rose to KRW 2.74 billion in the third quarter of 2026 after a return to profit in the second quarter.

Net income attributable to controlling shareholders over the last four quarters totals KRW 3.21 billion, so the earnings base is still small.

Bullish factors include demand for EU-driven replacement materials, a larger subsidiary backlog and joint development projects, while bearish factors include a lower operating margin, higher financing costs and borrowing, and a higher debt-to-equity ratio.

The pharmaceutical unit is holding steady in sales, and licensing results are not yet reflected in reported figures. The next checkpoints are the operating margin and debt structure in the 2026 annual business report, followed by how much backlog converts to revenue in the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. supple.kr
  2. thebk.co.kr
  3. fnnews.com
  4. bloter.net
  5. meconomynews.com
  6. fnnews.com
  7. medipharmhealth.co.kr
  8. news.nate.com
  9. m.news.nate.com
  10. dailypharm.com
  11. vegannews.co.kr
  12. medipharmhealth.co.kr
  13. view.asiae.co.kr
  14. news.mtn.co.kr
  15. geconomy.co.kr
  16. newspim.com
  17. beautytravelnews.com
  18. getnews.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis